A Phase-i Clinical-trial and Pharmacokinetic Evaluation of Liposome-encapsulated Doxorubicin

We have treated 14 cancer patients with liposomeencapsulqted doxorubicin (LED) at doses of 30, 45, 60, and 90 mg/m ². Nausea and vomiting, phlebitis, and stomatitis were minimal or absent at each dose, but dose-limiting granulocytopenia occurred at 90 mg/ m2. Thrombocytopenia and/or anemia also occurred in all patients treated at 60 or 90 mg/m ². Complete alopecia was seen in one of three cases at 60 mg/m ² and all cases at 90 mg/m ². No hepatic, renal, or other major organ toxicities were encountered. Clinical cardiac toxicity did not occur in any patient, but the cumulative doxorubicin doses in 13 cases were less than 400 mg/m ². The plasma elimination of LED out to 24 hours was analyzed in terms of a twocompartment model. Depending upon the dose and the infusion time, maximum plasma concentrations ranged from 2.6 μmol/L to 36.89 μmol/L and the area under the plasma concentration × time curve (AUC) values ranged from 1.86 μmol/L × h/L to 49.57 μmol × h/L. These values are significantly higher than those expected for free doxorubicin. Urinary excretion of LED was approximately 10% after 24 hours. Doxorubicinol and doxorubicinone appeared at low levels in plasma 12 to 24 hours after injection. LED pharmacokinetics differ from those of free drug by the higher plasma levels and AUC of doxorubicin achieved, and by the low conversion of LED to metabolites. Overall, LED was well tolerated and produced only moderate nausea and vomiting and little stomatitis at myelosuppressive doses. The study also suggested that LED produces less venous sclerosis than free doxorubicin, but this requires further clinical verification.